ACRSAclaris Therapeutics, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 11267
Ticker: ACRS
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2015-10-07
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ACRS

Detail

Enriched 2026-08-14 20:47

Market cap: $859,641,535.12
Shares outstanding (class): 139,824,273
Shares outstanding (weighted): 147,198,893
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 73
Location: WAYNE, PA
Homepage: https://www.aclaristx.com
Description: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Market cap and share counts drift.

Funds holding this security

71 funds · 71 positions · $45.55M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$14.89M	0.00%	3,969,645 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$8.52M	0.01%	2,271,724 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$4.11M	0.01%	1,096,528 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$3.02M	0.02%	804,808 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$2.87M	0.04%	766,012 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$2.22M	0.09%	592,568 NS	FIGI
JPMorgan Small Cap Value Fund JPMorgan Trust II	—	$1.05M	0.09%	280,173 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.00M	0.00%	267,101 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$867.0K	0.07%	231,208 NS	FIGI
SMALL COMPANY GROWTH PORTFOLIO VANGUARD VARIABLE INSURANCE FUNDS	—	$742.6K	0.05%	198,014 NS	FIGI
Ultra-Small Company Market Fund Bridgeway Funds, Inc.	—	$626.3K	0.51%	167,019 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$589.7K	0.01%	157,263 NS	FIGI
Ultra-Small Company Fund Bridgeway Funds, Inc.	—	$562.5K	0.66%	150,000 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$429.5K	0.01%	114,522 NS	FIGI
Fidelity Small Cap Value Index Fund Fidelity Salem Street Trust	—	$428.2K	0.02%	114,180 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERACRS
FIGI_COMPOSITEBBG003LF0QR9
FIGI_SHARE_CLASSBBG003LF0QS8
CIK0001557746
ISINUS00461U1051
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Aclaris Therapeutics is a biopharmaceutical company focused on dermatology, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.